Novavax, Inc. (NVAX)
7.46
-0.36
(-4.66%)
USD |
NASDAQ |
Jul 24, 16:00
7.50
+0.04
(+0.54%)
After-Hours: 20:00
Novavax Enterprise Value : 731.32M for July 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| July 24, 2026 | 731.32M |
| July 23, 2026 | 791.33M |
| July 22, 2026 | 805.31M |
| July 21, 2026 | 832.44M |
| July 20, 2026 | 800.38M |
| July 17, 2026 | 854.64M |
| July 16, 2026 | 859.57M |
| July 15, 2026 | 890.81M |
| July 14, 2026 | 889.16M |
| July 13, 2026 | 969.73M |
| July 10, 2026 | 1.039B |
| July 09, 2026 | 1.050B |
| July 08, 2026 | 1.042B |
| July 07, 2026 | 1.060B |
| July 06, 2026 | 1.042B |
| July 02, 2026 | 1.106B |
| July 01, 2026 | 1.060B |
| June 30, 2026 | 1.054B |
| June 29, 2026 | 1.044B |
| June 26, 2026 | 964.80M |
| June 25, 2026 | 912.18M |
| June 24, 2026 | 968.09M |
| June 23, 2026 | 984.53M |
| June 22, 2026 | 984.53M |
| June 18, 2026 | 1.006B |
| Date | Value |
|---|---|
| June 17, 2026 | 1.067B |
| June 16, 2026 | 1.017B |
| June 15, 2026 | 1.019B |
| June 12, 2026 | 964.80M |
| June 11, 2026 | 989.46M |
| June 10, 2026 | 912.18M |
| June 09, 2026 | 930.27M |
| June 08, 2026 | 922.05M |
| June 05, 2026 | 1.065B |
| June 04, 2026 | 1.180B |
| June 03, 2026 | 1.182B |
| June 02, 2026 | 1.183B |
| June 01, 2026 | 1.233B |
| May 29, 2026 | 1.308B |
| May 28, 2026 | 1.202B |
| May 27, 2026 | 1.328B |
| May 26, 2026 | 1.225B |
| May 22, 2026 | 1.019B |
| May 21, 2026 | 981.24M |
| May 20, 2026 | 1.029B |
| May 19, 2026 | 968.09M |
| May 18, 2026 | 973.02M |
| May 15, 2026 | 994.39M |
| May 14, 2026 | 1.042B |
| May 13, 2026 | 1.022B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 17.56B |
| Pfizer Inc. | 191.54B |
| Agenus, Inc. | 493.07M |
| Fate Therapeutics, Inc. | 182.18M |
| Recursion Pharmaceuticals, Inc. | 983.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.491M |
| Revenue (Quarterly) | 139.51M |
| Total Expenses (Quarterly) | 149.00M |
| EPS Diluted (Quarterly) | -0.0581 |
| Gross Profit Margin (Quarterly) | 78.00% |
| Profit Margin (Quarterly) | -6.80% |
| Earnings Yield | -8.01% |
| Operating Earnings Yield | 2.99% |
| Normalized Earnings Yield | 0.1032 |